Guggenheim Maintains Buy Rating on Ultragenyx Pharmaceutical, Lowers Price Target to $24
Guggenheim analyst Debjit Chattopadhyay has maintained a 'Buy' rating on Ultragenyx Pharmaceutical Inc. while adjusting the price target downward from $35 to $24.